Sector
PharmaceuticalsOpen
₹565.65Prev. Close
₹565.1Turnover(Lac.)
₹1.06Day's High
₹565.65Day's Low
₹565.6552 Week's High
₹1,175.952 Week's Low
₹405Book Value
₹146.52Face Value
₹2Mkt Cap (₹ Cr.)
8,902.99P/E
55.28EPS
10.23Divi. Yield
0The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Equity Capital | 30.62 | 28.61 | 28.61 | 14.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,274.63 | 115.27 | 282.89 | 171.23 |
Net Worth | 2,305.25 | 143.88 | 311.5 | 185.54 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Gross Sales | 4,118.16 | 4,178.18 | 3,654.82 | 3,671.89 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 4,118.16 | 4,178.18 | 3,654.82 | 3,671.89 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 68.82 | 34.03 | 46.11 | 22.83 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,672.5 | 93.87 | 4,01,372.75 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,938 | 83.3 | 1,84,017.51 | 667 | 0.43 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,488.3 | 24.97 | 1,20,199.04 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,322.4 | 59.44 | 1,12,475.6 | 474 | 0.18 | 2,385 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,283.8 | 19.91 | 1,07,151.95 | 1,200.7 | 0.62 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
SANDEEP JAIN
Managing Director
SANJEEV JAIN
Independent Director
Matangi Gowrishankar
Company Sec. & Compli. Officer
Dharamvir Malik
Independent Director
Kewal Kundanlal Handa
Whole-time Director
Sanjay Sinha
Non Executive Director
SUNIL KUMAR THAKUR
Independent Director
SATWINDER SINGH
Independent Director
Anil Kumar Arvindlal Amin
304 Mohan Place LSC Saraswati,
Vihar,
Delhi - 110034
Tel: +91 11 6904 1000
Website: http://www.akums.in
Email: cs@akums.net
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the...
Read More
Reports by Akums Drugs & Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.